Narrative review · PMID 41490200
Therapeutic peptides in orthopaedic injuries — CJC-1295 + Ipamorelin for IGF-1 signaling and satellite cell repair — VialBase Research
CJC-1295 + ipamorelin activate IGF-1 signaling and satellite cell repair
Last updated · 2026 · Various · Orthopaedic Review
Key findings
- CJC-1295 + ipamorelin activate IGF-1 signaling and satellite cell repair
- GHRH + GHRP synergy produces amplified GH pulses beneficial for musculoskeletal recovery
- No dedicated orthopaedic clinical trials exist for the combination
- Mechanistic plausibility is strong but clinical validation is missing
Summary
Narrative review evaluating popular injectable therapeutic peptides for orthopaedic injuries. CJC-1295 + ipamorelin are evaluated as a growth hormone secretagogue combination that activates IGF-1 signaling and satellite cell repair for musculoskeletal recovery.
Key Findings
- The CJC-1295 + ipamorelin combination activates IGF-1 signaling cascade
- IGF-1 promotes satellite cell proliferation and differentiation — critical for muscle repair
- GHRH (CJC-1295) + GHRP (ipamorelin) synergy produces GH pulses greater than either alone
- Preclinical evidence supports the mechanism but no orthopaedic clinical trials exist
Relevance to Ipamorelin
Validates the mechanistic basis for CJC-1295 + ipamorelin stacking in recovery contexts. The IGF-1 → satellite cell pathway is the core rationale for using GH secretagogues in musculoskeletal injury. Confirms the stack as the standard approach while noting the evidence gap.
Citation
Orthopaedic Review. 2026. PMID: 41490200
See Also
- Parent compound: Ipamorelin
- CJC-1295